Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 63, Issue 4, 2007, Pages 459-468

  Stypinski, Daria ^a   Obaidi, Mohammad ^a   Combs, Michelle ^a   Weber, Meg ^a   Stewart, Adrian J ^b   Ishikawa, Hiroaki ^c  

^a MDS Inc   (Canada)

^b MDS Pharma Services   (United Kingdom)

^c ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

Immunosuppression; Mizoribine; Pharmacokinetics; Renal transplant; Safety

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MIZORIBINE; PLACEBO; URIC ACID;

ARTHRALGIA; ARTICLE; CAUCASIAN; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; EYE PAIN; FLU LIKE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CLEARANCE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SORE THROAT; STANDARD; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; RIBONUCLEOSIDES; TREATMENT OUTCOME;

EID: 33947199783     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02779.x     Document Type: Article

References (14)

1. Hardy M, Cohen D. Message from the Directors of Renal Transplantation Program. New York: Columbia University Department of Surgery, Columbia University Medical Center 1999-2005. Available at http://www.columbiasurgery. org/programs/tx_renal (last accessed: 22 April 2005).
2. Parker S. Renal Transplantation. Coventry, UK: Surgical tutor. 1997-2005. Updated 15 January 2005. Available at http://www.surgicaltutor.org.uk/system/ urinary/renal_transplant.htm (last accessed: 22 April 2005).
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-29.
4. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K. Studies on Bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 1974; 27: 775-82.
5. Koyama H, Tsuji M. Genetic and biochemical studies on the activation and cytotoxic mechanism of Bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol 1983; 32: 3547-53.
6. Matsumoto K, Morino T, Hara T, Yano J, Tujino M, Mizuno K, Yamamoto H. A comparative, subacute toxicity study of mizoribine and azathioprine in dogs - with particular reference to hepatotoxicity, nephrotoxicity and hematotoxicity. Japan J Transplant 1982; 17 (Suppl.): 603-14.
7. Liu D, Kobayashi T, Nagasaka T, Yokoyama I, Ma Y, Miwa Y, Kuzuya T, Morozumi K, Oikawa T, Shimano Y, Takeuchi O, Uchida K, Nakao A. Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. Transplant Int 2005; 18: 401-7.
8. Takada K, Asada S, Ichikawa Y, Sonoda T, Takahara S, Nagano S, Fukunishi T. Pharmacokinetics of Bredinin in renal transplant patients. Eur J Clin Pharmacol 1983; 24: 457-61.
9. Akiyama T, Matsuura T, Iguchi M, Kurita T. Clinical experience in the use of and a pharmacokinetic study of Bredinin in renal transplantation. Japan J Transplant 1982; 17 (Suppl.): 753-60.
10. Micromedex, Inc. Mizoribine 2003. Available at http://csi.micromedex.com/ DKS/DATA/DE/DE2064.HTM?Top=Yes (last accessed: 21 April 2005).
11. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. Clin Invest 1991; 87: 940-8.
12. Akiyama T, Okazaki H, Takahashi K, Hasegawa A, Tanabe K, Uchida K, Takahara S, Toma H. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan. Transplantation Proc 2005; 37: 843-5.
13. Hosotsubo H, Takahara S, Taenaka N. Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum. J Chromatogr 1988; 432: 340-5.
14. Gough K, Hutchinson M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Information J 1995; 29: 1039-48.